2,135
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Eli Lilly's recently active trials. Comparator arms are excluded.
- Orforglipron13 trials
- Tirzepatide11 trials
- Mirikizumab9 trials
- Eloralintide6 trials
- Baricitinib4 trials
- Brenipatide4 trials
Upcoming readouts
Next primary completion dates among Eli Lilly's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Dec 2026A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in…Phase 2
- Feb 2027ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Phase 3
- Mar 2027SOLARIS-1: A Study of Solbinsiran (LY3561774) in Participants With Severe HypertriglyceridemiaPhase 2
- Mar 2027A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adul…Phase 2
- Apr 2027BP07: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Bac…Phase 2
- Apr 2027OA07: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis …Phase 2
Top therapeutic areas
Conditions studied most often across Eli Lilly's recently active trials.
- Obesity19 trials
- Overweight16 trials
- Type 2 Diabetes6 trials
- Overweight or Obesity5 trials
- Alzheimer Disease5 trials
- Carcinoma, Non-Small-Cell Lung4 trials
Eli Lilly pipeline by phase
The main study drugs across 238 active trials Eli Lilly leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 323 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Orforglipron | 17 | 7 | Feb 2027 est. | NCT07794579 · NCT07790861 · NCT07668336 |
| BrenipatideLY3537031 | 15 | 11 | Feb 2027 est. | NCT07775300 · NCT07412756 · NCT07219966 |
| AbemaciclibLY2835219 | 13 | — | Feb 2027 est. | NCT05288166 · NCT05169567 · NCT03155997 |
| EloralintideLY3841136 | 12 | 9 | Oct 2026 est. | NCT07392190 · NCT07369011 · NCT07353931 |
| Retatrutide | 9 | — | Oct 2026 est. | NCT07357415 · NCT07232719 · NCT07035093 |
| Donanemab | 8 | 4 | Nov 2027 est. | NCT07602582 · NCT07571161 · NCT05738486 |
| Baricitinib | 6 | 4 | Oct 2026 est. | NCT07222332 · NCT07222137 · NCT05723198 |
| SelpercatinibLOXO-292 | 6 | — | — | NCT04819100 · NCT04211337 · NCT04194944 |
| ImlunestrantLY3484356 | 5 | 1 | Oct 2027 est. | NCT05514054 · NCT04975308 · NCT07287098 |
| OlomorasibLY3537982 | 4 | 2 | Apr 2027 est. | NCT06890598 · NCT06119581 · NCT07814417 |
| Ramucirumab | 3 | 1 | May 2027 est. | NCT02411448 · NCT05999994 · NCT02711553 |
| Galcanezumab | 2 | — | — | NCT04616326 · NCT03432286 |
| LY4064809STX-478 | 2 | 2 | May 2029 est. | NCT07174336 · NCT05768139 |
| RemternetugLY3372993 | 2 | — | Apr 2029 est. | NCT06653153 · NCT07346495 |
| Vepugratinib | 2 | 2 | Jun 2027 est. | NCT07218380 · NCT05614739 |
| [Lu-177]-PNT2002 | 1 | — | — | NCT04647526 |
| Dulaglutide | 1 | 1 | Dec 2027 est. | NCT06739122 |
| Ixekizumab | 1 | — | — | NCT04527380 |
| Lepodisiran | 1 | 1 | Dec 2029 est. | NCT07613294 |
| Lepodisiran Sodium | 1 | — | Mar 2029 est. | NCT06292013 |
| Muvalaplin | 1 | 1 | Mar 2031 est. | NCT07157774 |
| P-tau217 Test | 1 | 1 | Jul 2033 est. | NCT07142954 |
| Sofetabart Mipitecan | 1 | 1 | Nov 2028 est. | NCT07213804 |
Phase 218 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| LY4268989MORF-057 | 5 | 4 | Oct 2026 est. | NCT07415044 · NCT07186101 · NCT06226883 |
| LY4065967 | 3 | 3 | Apr 2027 est. | NCT07641517 · NCT07641504 · NCT07285018 |
| Macupatide | 3 | 2 | Mar 2027 est. | NCT07589608 · NCT07215559 · NCT07765511 |
| EltrekibartLY3041658 | 2 | 1 | Dec 2027 est. | NCT06598943 · NCT07545590 |
| LY3938577 | 2 | 1 | Nov 2026 est. | NCT07215312 · NCT06280703 |
| LY4005130 | 2 | 2 | May 2027 est. | NCT07533019 · NCT07533006 |
| 120 mg LY2784544 | 1 | — | — | NCT01594723 |
| Bimagrumab | 1 | — | — | NCT06643728 |
| Clazakizumab | 1 | — | May 2027 est. | NCT07783802 |
| LY3016859 ISA | 1 | 1 | Apr 2027 est. | NCT05986292 |
| LY3305677 | 1 | 1 | Sept 2027 est. | NCT06143956 |
| LY3457263 | 1 | 1 | May 2027 est. | NCT06897475 |
| LY3537021 | 1 | 1 | Dec 2026 est. | NCT07169851 |
| LY3541860 | 1 | — | — | NCT06220669 |
| LY4395089 | 1 | 1 | Jun 2027 est. | NCT07483099 |
| LY4515100 | 1 | 1 | Nov 2026 est. | NCT07511816 |
| Mirikizumab - Intravenous (IV) | 1 | 1 | Jun 2027 est. | NCT07483073 |
| Solbinsiran | 1 | 1 | Mar 2027 est. | NCT07269210 |
Phase 147 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| LY4256984 | 3 | 3 | Aug 2027 est. | NCT07571200 · NCT07571174 · NCT07100119 |
| LY3410738 | 2 | — | — | NCT04603001 · NCT04521686 |
| LY3884961 | 2 | — | Mar 2031 est. | NCT05487599 · NCT04127578 |
| LY3971297 | 2 | 1 | Nov 2027 est. | NCT07547540 · NCT06148272 |
| LY4405094 | 2 | — | Jan 2028 est. | NCT07787182 · NCT07787169 |
| [Ac-225]-PSMA-62 (mCRPC) | 1 | — | Sept 2027 est. | NCT06229366 |
| Abemaciclib Tablet (Test Formulation) | 1 | — | Nov 2026 est. | NCT07818967 |
| LOXO-783 | 1 | 1 | Dec 2026 est. | NCT05307705 |
| LY3200882 | 1 | — | — | NCT02937272 |
| LY3295668 Erbumine | 1 | — | — | NCT04106219 |
| LY3439539 | 1 | 1 | Aug 2027 est. | NCT07598370 |
| LY3867070 | 1 | 1 | — | NCT07021547 |
| LY3884963 | 1 | — | Nov 2029 est. | NCT04408625 |
| LY3954068 | 1 | 1 | Feb 2027 est. | NCT06297590 |
| LY3962673 | 1 | 1 | Mar 2029 est. | NCT06586515 |
| LY3962681 | 1 | 1 | Jul 2030 est. | NCT06565195 |
| LY3981314 | 1 | — | Feb 2027 est. | NCT07005284 |
| LY4006895 | 1 | 1 | Jul 2027 est. | NCT06657768 |
| LY4006896 | 1 | 1 | Jan 2028 est. | NCT06809400 |
| LY4050784 | 1 | 1 | Oct 2027 est. | NCT06561685 |
| LY4052031 | 1 | 1 | May 2027 est. | NCT06465069 |
| LY4057996 SC | 1 | 1 | Dec 2026 est. | NCT06945406 |
| LY4066434. | 1 | — | Jan 2030 est. | NCT06607185 |
| LY4066708 | 1 | 1 | Sept 2027 est. | NCT07046559 |
| LY4088044 | 1 | 1 | Jul 2027 est. | NCT07090785 |
| LY4101174 | 1 | — | Mar 2027 est. | NCT06238479 |
| LY4152199 - IV | 1 | 1 | Apr 2027 est. | NCT07101328 |
| LY4167586 | 1 | — | Dec 2026 est. | NCT07225556 |
| LY4174794 | 1 | 1 | Apr 2029 est. | NCT07654972 |
| LY4175408 | 1 | 1 | Jul 2030 est. | NCT07046923 |
| LY4178256 | 1 | 1 | Mar 2028 est. | NCT07698210 |
| LY4213663 | 1 | 1 | Mar 2028 est. | NCT07258849 |
| LY4214835 | 1 | 1 | Jan 2027 est. | NCT07258836 |
| LY4226695 | 1 | — | Jul 2027 est. | NCT07767487 |
| LY4257496 | 1 | 1 | Apr 2030 est. | NCT07114601 |
| LY4298445 | 1 | 1 | Mar 2028 est. | NCT07276958 |
| LY4302814 | 1 | 1 | Aug 2027 est. | NCT07566338 |
| LY4329090 | 1 | — | Sept 2027 est. | NCT07808073 |
| LY4337713 | 1 | 1 | Jul 2028 est. | NCT07213791 |
| LY4355756 | 1 | — | Jan 2027 est. | NCT07765498 |
| LY4515100 via SAD | 1 | 1 | Mar 2027 est. | NCT07339722 |
| LY4584180 | 1 | 1 | Apr 2027 est. | NCT07226843 |
| LY5625575 | 1 | — | Aug 2027 est. | NCT07801300 |
| Methylprednisolone | 1 | — | Feb 2027 est. | NCT04411654 |
| Olomorasib test | 1 | — | Oct 2026 est. | NCT07794592 |
| Sofe-M | 1 | 1 | Jun 2029 est. | NCT06400472 |
| Tersolisib | 1 | — | — | NCT07662798 |
Phase 44 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Tirzepatide | 15 | 5 | Nov 2026 est. | NCT07438444 · NCT07247084 · NCT06864026 |
| Pirtobrutinib | 11 | 6 | Oct 2026 est. | NCT07218341 · NCT06876662 · NCT06876649 |
| Mirikizumab | 8 | 6 | Feb 2027 est. | NCT07612267 · NCT06937099 · NCT06937086 |
| LebrikizumabLY3650150 | 6 | 1 | May 2027 est. | NCT07006792 · NCT06339008 · NCT06338995 |
Derived from 238 active trials Eli Lilly leads; 238 name an intervention, folding into 92 phased drugs. 2 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Eli Lilly's own pipeline disclosure.
Eli Lilly trials
The 50 most significant of Eli Lilly's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy ParticipantsNCT07794592Olomorasib test | Phase 1 | Not yet scored | OngoingNot yet recruiting | 24 est. | Oct 2026 |
| A Study of Abemaciclib (LY2835219) in Healthy ParticipantsNCT07818967Abemaciclib Tablet (Test Formulation) | Phase 1 | Not yet scored | OngoingNot yet recruiting | 15 est. | Nov 2026 |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerNCT07169851LY3537021 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 204 est. | Dec 2026 |
| PIKASSO-01A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705LOXO-783 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 260 est. | Dec 2026 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744Tirzepatide | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 18 est. | Dec 2026 |
| ADVANCEA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Orforglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 125 est. | Feb 2027 |
| SOLARIS-1A Study of Solbinsiran (LY3561774) in Participants With Severe HypertriglyceridemiaNCT07269210Solbinsiran | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | Mar 2027 |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Macupatide | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | Mar 2027 |
| BP07A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainNCT07641504LY4065967 | Phase 2 | Not yet scored | OngoingRecruiting | 150 est. | Apr 2027 |
| OA07A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainNCT07641517LY4065967 | Phase 2 | Not yet scored | OngoingRecruiting | 150 est. | Apr 2027 |
| BAF_FRontier-1A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )NCT07101328LY4152199 - IV | Phase 1 | Locked · track to reveal | OngoingRecruiting | 215 est. | Apr 2027 |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersNCT07226843LY4584180 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 460 est. | Apr 2027 |
| A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)NCT06338995LY3650150 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 510 est. | May 2027 |
| ACHIEVE-RAMA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307Orforglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 130 est. | May 2027 |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475LY3457263 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | May 2027 |
| TOPAZ-UCLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:NCT07186101LY4268989 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 252 est. | May 2027 |
| A Study of LY4005130 in Adult Participants With Non-Segmental VitiligoNCT07533019LY4005130 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 66 est. | May 2027 |
| NEXUS-01A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069LY4052031 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 420 est. | May 2027 |
| CLARITY-CRPA Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventNCT07783802Clazakizumab | Phase 2 | Not yet scored | OngoingNot yet recruiting | 120 est. | May 2027 |
| A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)NCT07533006LY4005130 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | Jun 2027 |
| A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseNCT07483073Mirikizumab - Intravenous (IV) | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | Jun 2027 |
| A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseNCT07483099LY4395089 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | Jun 2027 |
| A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightNCT07808060Eloralintide | Phase 1 | Not yet scored | OngoingNot yet recruiting | 34 est. | Jun 2027 |
| RENEW-IBS-CA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)NCT07545772LY3537031 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 342 est. | Jul 2027 |
| A Study of LY3439539 in Participants With Alzheimer's DiseaseNCT07598370LY3439539 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | Aug 2027 |
| A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)NCT07801300LY5625575 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 204 est. | Aug 2027 |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956LY3305677 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 1,481 est. | Sept 2027 |
| RENEW-IBS-DA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)NCT07545759LY3537031 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 531 est. | Sept 2027 |
| A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07808073LY4329090 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 184 est. | Sept 2027 |
| A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Tirzepatide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | Oct 2027 |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685LY4050784 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 340 est. | Oct 2027 |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026Tirzepatide | Phase 4 | Locked · track to reveal | OngoingRecruiting | 200 est. | Nov 2027 |
| SUNRAY-01A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581LY3537982 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,264 est. | Nov 2027 |
| A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)NCT07286175Brenipatide | Phase 2 | Locked · track to reveal | OngoingRecruiting | 400 est. | Nov 2027 |
| RENEW-Scz-1A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507Brenipatide | Phase 2 | Locked · track to reveal | OngoingRecruiting | 450 est. | Nov 2027 |
| A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Orforglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 150 est. | Dec 2027 |
| AMAYA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseNCT05509777Mirikizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 90 est. | Dec 2027 |
| ENLIGHTEN-2A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600Eloralintide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,035 est. | Jan 2028 |
| A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's DiseaseNCT07787182LY4405094 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 68 est. | Jan 2028 |
| BRAVE-AA-PEDSA Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataNCT05723198Baricitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 595 est. | Mar 2028 |
| ENLIGHTEN-3A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011Eloralintide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 800 est. | Mar 2028 |
| ENLIGHTEN-4Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931Eloralintide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 900 est. | Mar 2028 |
| RESTRAIN-SUIA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884Orforglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,000 est. | Mar 2028 |
| RENEW-Op-1A Study of Brenipatide in Participants With Opioid Use DisorderNCT07420283Brenipatide | Phase 2 | Locked · track to reveal | OngoingRecruiting | 465 est. | Mar 2028 |
| A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07276958LY4298445 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 68 est. | Mar 2028 |
| ATTAIN-CNA Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861Orforglipron | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 192 est. | Mar 2028 |
| ATTAIN-OA PAINA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471Orforglipron | Phase 3 | Locked · track to reveal | OngoingRecruiting | 800 est. | Apr 2028 |
| COMMIT-UCMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Mirikizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 350 est. | Apr 2028 |
| RENEW-ALC-1A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderNCT07219966LY3537031 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,100 est. | Apr 2028 |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942Tirzepatide | Phase 4 | Locked · track to reveal | OngoingRecruiting | 200 est. | May 2028 |